enGene (NASDAQ: ENGN) is a late-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, whose lead product candidate, detalimogene voraplasmid, is being evaluated in an ongoing pivotal study for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive to BCG. Detalimogene voraplasmid was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.
ROLE
enGene Inc. is currently seeking a qualified and motivated candidate who will play a key role in the Research and Development (R&D) group. In collaboration with project leaders, the Associate Scientist will provide expertise to a team responsible for synthesizing new polymers and developing and optimizing formulations to support gene therapy pipeline development.
The candidate will work in a dynamic, fast-paced, and highly collaborative environment, as well as perpetuate the company culture that promotes our values (Patient-focused, Integrity, Innovation and Teamwork).